A Phase 4 interventional study of Methadone hydrochloride and Fentanyl/Hydromorphone in Cleft Palate, Pain and Postoperative Care, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 6 Months to 4 Years. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Duke University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Cleft Palate with a site in United States — 9 open to participants now, 11 under way, 1 of them phase 3. Cleft Palate · United States.
Among the 31 studies in Cleft Palate with a site in United States, this one is the 9th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 in phase 4, reaches primary completion later than 6 of the 10 other live ones, and was the 28th registered.
123 studies on the registry are indexed under Cleft Palate; 35 are open to participants now.
Browse Cleft Palate studies →9 of the 31 studies in Cleft Palate with a site in United States are open now. Recruiting first, the newest first:
Phoenix Children's Hospital · Sites in United States
Ages 0 mo–12 mo
Noel Jabbour · Sites in United States
Ages 5–17
Medical University of South Carolina · Sites in United States
Ages 6–18
Kerry O'Rourke · Sites in United States
Ages 6+
Seattle Children's Hospital · Sites in United States
Ages 20 mo–32 mo
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Cleft Palate studies recruiting now, 3 (14%) set no upper age limit and 18 (86%) stop at 75 or younger; 20 take children under 18; 2 take healthy volunteers.
This study: 6 Months to 4 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 2 · Phase 4 2
First in 1996; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 44 across 77 interventional studies indexed under Cleft Palate.
Median enrollment 47 across the 22 interventional studies, 130 across the 9 observational. Of the 18 that completed or were terminated, 5 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 31 has an industry lead sponsor. The 10 most frequent:
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
Duke University has 2 studies filed under Cleft Palate — fewer than ten, so there is no comparison to draw.
5 of the studies in Cleft Palate with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07219901Old Dominion UniversityEarly Intervention in Infants With Unrepaired Cleft Palate: Language, Palatal Function, and Articulation. | 2026-12-31 |
| NCT06420336Medical University of South CarolinaQL vs LAI for Palatoplasty | 2027-01-01 |
| NCT05492266Noel JabbourExpiratory Muscle Strength Training for Hypernasal Speech in Children | 2027-05 |
| NCT03632044University of FloridaEvaluation of Trigeminal Nerve Blockade | 2027-05-31 |
| NCT06962306Duke UniversityOptimizing Perioperative Analgesia to Lower Pain Following Cleft Palate Surgery | 2027-06-04 |
Add all 5 to your calendar (.ics) → With an account.
Among the 31 studies in Cleft Palate with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the use of short acting opioids (fentanyl/hydromorphone) with long acting opioids (methadone) for pain control following cleft palate surgery in infants and young children.
This is a single center, randomized, double blind, parallel-group dose escalation investigation in infants and children undergoing cleft palate surgery which will compare post operative pain control indices for patients receiving short acting versus long acting opioids as perioperative analgesics. Surgical and anesthesia care, except for opioid management, are not altered for study purposes. Subjects are randomized 2:1 to either long-duration (methadone) or short-duration opioid (fentanyl, hydromorphone) through the perioperative period. Exploratory data will be collected for up to 30 days post-operatively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Methadone 0.2-0.25 mg/kg actual body weight
Drug: Methadone hydrochloride
Fentanyl/Hydromorphone per routine care
Drug: Fentanyl/Hydromorphone
Initial dosing 0.2mg/kg, potential to escalate to 0.25mg/kg following interim analysis
Drug pages: FentanylStudies of FentanylFentanyl pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · HydromorphoneStudies of HydromorphoneHydromorphone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Per routine care
Total amount of opioids medication administered
Post-PACU in-hospital opioid use in oral morphine milligram equivalents (OMEs) per kilogram through POD1
Time frame: From PACU discharge through postoperative day 1 (POD1)
Total amount of opioid medications administered
Total (post-PACU in-hospital and post-discharge) opioids used (number of daily doses and OME/kg)
Time frame: Up to 7 days after surgery
Postanesthesia Care Unit (PACU) opioid medication administration
Binary (yes/no) need for opioid administration in the PACU
Time frame: Up to 6 hours after surgery
Area under the curve (AUC) pain trajectories
In-hospital AUC pain trajectories calculated from pain intensity scores on the Face, Legs, Activity, Cry, Consolability (FLACC) pain scale. The FLACC pain scale has a range of 0 to 10, where 0=no pain and 10=worst possible pain.
Time frame: Through hospital discharge (up to 4 days)
Average daily pain intensity
Average daily pain scores using the Face, Legs, Activity, Cry, Consolability (FLACC) pain scale. The FLACC pain scale has a range of 0 to 10, where 0=no pain and 10=worst possible pain.
Time frame: Up to 7 days after surgery
Plan to share: Yes — De-identified data will be shared at the discretion of the PI upon reasonable request.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: IPD will be available 1 year after study completion.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Methadone · Fentanyl · Hydromorphone